🇺🇸 peginterferon alpha 2a in United States

23 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 5 reports (21.74%)
  2. Depression — 2 reports (8.7%)
  3. Hepatitis C Antibody Positive — 2 reports (8.7%)
  4. Hepatotoxicity — 2 reports (8.7%)
  5. Hypersensitivity — 2 reports (8.7%)
  6. Immune Reconstitution Syndrome — 2 reports (8.7%)
  7. Insulin Resistance — 2 reports (8.7%)
  8. Liver Injury — 2 reports (8.7%)
  9. Myocardial Ischaemia — 2 reports (8.7%)
  10. Pain — 2 reports (8.7%)

Source database →

peginterferon alpha 2a in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is peginterferon alpha 2a approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for peginterferon alpha 2a in United States?

Beijing Ditan Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.